Astrazeneca (AZNCF) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.8 billion.
- Astrazeneca's Income towards Parent Company rose 8466.67% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.9 billion, marking a year-over-year increase of 5633.55%. This contributed to the annual value of $12.9 billion for FY2025, which is 8365.32% up from last year.
- Per Astrazeneca's latest filing, its Income towards Parent Company stood at $2.8 billion for Q4 2025, which was up 8466.67% from $2.6 billion recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Income towards Parent Company registered a high of $4.0 billion during Q1 2025, and its lowest value of -$2.0 billion during Q3 2021.
- Its 5-year average for Income towards Parent Company is $1.6 billion, with a median of $1.7 billion in 2022.
- In the last 5 years, Astrazeneca's Income towards Parent Company crashed by 28233.67% in 2021 and then surged by 58870.97% in 2023.
- Over the past 5 years, Astrazeneca's Income towards Parent Company (Quarter) stood at -$747.0 million in 2021, then skyrocketed by 329.18% to $1.7 billion in 2022, then grew by 4.03% to $1.8 billion in 2023, then decreased by 15.78% to $1.5 billion in 2024, then skyrocketed by 84.67% to $2.8 billion in 2025.
- Its Income towards Parent Company stands at $2.8 billion for Q4 2025, versus $2.6 billion for Q3 2025 and $3.6 billion for Q2 2025.